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Edited by Giulio Superti-FurgaAbstract Chronic myeloid leukaemia (CML) is a myeloprolif-
erative disorder characterized by uncontrolled growth of
progenitor cells expressing the tyrosine kinase fusion gene prod-
uct, Bcr-Abl. At present, little is known regarding how TGFb,
and downstream Smad transcription factors, inﬂuence CML cell
proliferation in the context of Bcr-Abl expression. Here we show
that ectopic Bcr-Abl expression dramatically increases TGFb/
Smad-dependent transcriptional activity in Cosl cells, and that
this may be due to enhancement of Smad promoter activity.
Bcr-Abl expressing TF-1 myeloid cells are more potently growth
arrested by TGFb compared to the parental TF-1 cell line. Addi-
tionally, growth of Bcr-Abl-expressing CD34+ cells from
chronic phase CML patients is inhibited by TGFb and, interest-
ingly, treatment of a non-proliferating CD34+ CML cell sub-
population with the TGFb kinase inhibitor SB431542 enhanced
cell death mediated by the Bcr-Abl inhibitor imatinib. Our data
suggest that the expression of Bcr-Abl leads to hyper-responsive-
ness of myeloid cells to TGFb, and we hypothesise that this novel
cross-regulatory mechanism might play an important role in
maintaining the transformed progenitor cell population in CML.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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TGFb plays a vital role in maintaining the growth and dif-
ferentiation balance in haemopoietic cells [1,2]. Its speciﬁc
inﬂuence depends upon the cellular environment and diﬀeren-
tiation status. In general, TGFb is considered as a strong
inhibitor of committed progenitor cell function, and autocrine
production of TGFb maintains haemopoietic stem cells in a
quiescent state [3]. The intracellular components that trans-
duce TGFb signals into the nucleus have been unveiled in re-
cent years (reviewed in [4]). Smad transcription factors act
downstream of transmembrane serine–threonine kinase TGFb
receptors. To date, eight members of the Smad family have
been described that can be segregated into three functionally*Corresponding author. Fax: +44 1603 592250.
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complex induces phosphorylation of R-Smads (Smads 1, 2,
3, 5, 8), which then associate with a common-mediator co-
Smad (Smad4). These heteromeric complexes are translocated
to the nucleus, where they regulate gene transcription by asso-
ciation with DNA-binding proteins or direct binding to pro-
moters for target genes.
Despite the wealth of recent data on the molecular details of
TGFb signalling, little is known regarding how TGFb and
Smads inﬂuence chronic myeloid leukaemia (CML) cell prolif-
eration, although disruption of components within the TGFb
signalling cascade is known to drive many malignancies of
haemopoietic origin [1]. CML is an example of a myelopro-
liferative disorder characterized by the uncontrolled clonal
proliferation of transformed multipotent haemopoietic pro-
genitor cells. The disease usually evolves in three stages: the
chronic phase (CP), accelerated phase and blast crisis. Current
treatments, which include a variety of chemotherapeutic drugs,
stem cell transplantation, and more recently the Bcr-Abl
kinase inhibitor imatinib [5], are usually only eﬀective during
the CP. The complete eradication of CML using imatinib is,
however, hindered by a small pocket of resistant haemopoietic
stem cells that lead to disease persistance [6]. CML was the ﬁrst
type of leukaemia to be associated with a speciﬁc chromosomal
abnormality known as the Philadelphia (Ph) chromosome.
This is the consequence of a t(9;22)(q34;ql l) chromosomal
translocation which fuses part of the ABL proto-oncogene
with the BCR gene. The product of this translocation is the
constitutively active Bcr-Abl kinase [7], and Bcr-Abl leads to
the malignant transformation of haemopoietic cells through
several mechanisms linked to its activation of mitogenic signal-
ling pathways [8].
In this study, we investigated the eﬀects of Bcr-Abl expres-
sion on Smad/TGFb signalling activity. We show that Bcr-
Abl dramatically upregulates TGFb signalling when expressed
in Cosl cells via a mechanism that may involve enhancement of
Smad promoter activity. We also show that TGFb is a more
potent growth inhibitor of Bcr-Abl expressing TF-1 myeloid
cells compared to parental TF-1 cells. In addition, CD34+ cells
isolated from CP-CML patients are growth arrested by TGFb,
and are more susceptible to imatinib-mediated cell death fol-
lowing inhibition of the TGFb receptor kinase. Overall, our
ﬁndings deﬁne a new cross-regulatory mechanism that can
inﬂuence the growth of Bcr-Abl expressing haemopoietic cells,
and we speculate that combined treatment with both imatinib
and TGFb kinase inhibitors could provide added therapeutic
beneﬁts in CML patients.blished by Elsevier B.V. All rights reserved.
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2.1. Cell Culture and growth assays
CD34+ cells from three CP-CML patients were selected from leuk-
apheresis samples by binding to immunomagnetic beads (MiniMACS,
Miltenyi Biotech, Bergisch-Gerbach, Germany), and maintained in
RPMI-1640 medium with L-glutamine (Invitrogen), penicillin/strepto-
mycin (Sigma) and 10% fetal bovine serum (Sigma). The purity of the
CD34+ fraction after immunomagnetic selection was 94–98%, and
2 · 105 cells used routinely in each experiment. Cell fractionation
was performed on fresh leukapheresis samples, and the CD34+ cells
were cryopreserved in DMSO/FCS at 180 C in aliquots of 105–106
cells per vial, until thawed for the experiment. All three patients used
in this study were newly diagnosed as CML in chronic phase, with
WBC in the 160–235 · 109/L range, and none had received imatinib
or any other form of chemotherapy prior to leukapheresis. All three
patients had baseline level of BCR-ABL transcripts and 100% Ph+
metaphases. Although FISH was not performed, our experience from
a large number of patients who have very high WBC counts at diagno-
sis is that their CD34+ fraction contains <3%, if any, BCR-ABL-neg-
ative cells.
TF-1 cells expressing Bcr-Abl-GFP were generated using protocols
described previously [9], and maintained in RPMI-1640 medium with
L-glutamine (Invitrogen), penicillin/streptomycin (Sigma) and 10%
fetal bovine serum (Sigma) together with 5 ng/ml GM-CSF. In some
experiments, CP-CML cells were grown in the presence of the fol-
lowing: 1 ng/mL recombinant human interleukin-1b (rhIL-1b) and
50 ng/mL of rhIL-6, rhIL-3 and stem cell factor (hrSCF). Cos-1 cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium containing
10% fetal bovine serum. Cell growth curves were obtained using a
haematocytometer and non-viable cells excluded with trypan blue.
Growth of CD34 positive cells from CP-CML patients was assessed
using an automated cell counter (SYSMEX). HEK-293 cells
were transfected with Smad2-HA expression construct as described
[10].
2.2. Plasmids, reagents, and antibodies
Bcr-Abl p210 cloned into a pXMT2 expression vector was obtained
from Dr. Helen James (University of East Anglia, UK), CAGA12
from Caroline Hill (CRUK Laboratories, London, UK), pGL3-
Smad2P from Koichi Hagiwara (Saitama Medical School, Japan),
and Smad3P-luc from Thomas Kelley (Case Western Reserve Univer-
sity, USA). These plasmids were used for transient transfection of Cos-
1 cells using Fugene (Roche). Imatinib mesylate (STI571, Gleevec) was
obtained from Novartis Pharmaceuticals (Basel, Switzerland), and
SB431542 (TGFb-RI inhibitor) from Tocris Ltd. Antibodies used in-
cluded anti-phosphotyrosine (Sigma), anti-Smad2 and Smad3 (BD
transduction laboratories), anti-b-actin (Sigma), anti-Abl (Calbio-
chem). Secondary antibodies were HRP-conjugated goat anti-rabbit
or goat anti-mouse (Sigma).
2.3. Luciferase assay
Smad responsive reporter plasmid CAGA12 (2 lg) together with
cDNA constructs encoding Bcr-Abl (2 lg) and Renilla control plasmid
were transfected into Cos-1 cells in Dulbecco’s modiﬁed Eagle’s med-
ium with 0.5% fetal bovine serum using Fugene 6. Cells were stimu-
lated with TGFb1, and the transcriptional activity of the reporter
plasmid monitored by luciferase measurements (Roche). Smad pro-
moter activity was assessed by transfecting Cos-1 cells with 2 lg of
pGL3-Smad2P vector containing a 3030-bp fragment of the human
Smad2 promoter [11], or Smad3P-luc containing 1892 bp of the human
Smad3 promoter [12]. Empty pGL3 vector was used as a negative con-
trol. Each set of experiments was performed at least three times and the
results show the mean of the experiments with standard error bars.2.4. Cell lysate preparation and Western blots
Total cell extracts were obtained by lysing 0.8–1 · 107 cells in 150 lL
of buﬀer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100,
10% glycerol, and protease and phosphatase inhibitors). Lysates were
cleared by centrifugation at 12000 rpm and supernatant was isolated
and stored at 20 C. Normally, 100 lg of protein was separated by
SDS–PAGE and electroblotted onto nitrocellulose membrane. Mem-
branes were blocked in 3% bovine serum albumin (BSA) in phosphate
buﬀered saline (PBS), and then incubated overnight in the same buﬀercontaining the primary antibody. Following incubation with appropri-
ate secondary antibodies, membranes were visualised using ECL re-
agent (Amersham).2.5. FACS analysis
Cell cycle status was assessed following the staining of cells with pro-
pidium iodide (PI) and ﬂow cytometry analysis. Aliquots of 2 · 105
cells were washed in PBS and placed in 50% ice-cold ethanol for
30 min. After three PBS washes, cells were incubated with 100 lg/mL
PI/RNAse mix at room temperature in the dark for at least 1 h.
Stained cells were counted on a FACScan ﬂow cytometer (Becton
Dickinson), and the data obtained were analysed using WinMDI
and Cylchred. For determination of CD34 expression, aliquots of
2 · 105 cells were stained with 1 lL of CD34-PerCP antibody (Becton
Dickinson). After 30 min at 4 C in the dark, cells were washed twice in
PBS. Isotype-matched antibodies were used as negative controls to
establish the background ﬂuorescence of each sample. Stained cells
were analysed using a FACScan ﬂow cytometer (Becton Dickinson),
and the data obtained were analysed using WinMDI.3. Results
3.1. Bcr-Abl upregulates the transcriptional activity of a
Smad responsive reporter plasmid
Initially, we investigated potential cross-talk between the
TGFb signalling pathway and Bcr-Abl in Cosl cells, an epi-
thelial cell line that has been routinely been used to study
TGFb-dependent signalling activity. Cos-1 cells were trans-
fected with a Bcr-Abl expression plasmid together with a
TGFb/Smad-responsive luciferase reporter plasmid known
as CAGA12, which contains 12 tandem copies of a Smad/
DNA-binding element. Cells were stimulated with increasing
amounts of TGFb, and the luciferase activity in cell lysates
was monitored as a measure of the transcriptional activity
of the CAGA12 reporter plasmid. There was a signiﬁcant,
approximately 30-fold with Bcr-Abl vs. 12-fold w/o Bcr-Abl,
concentration-dependent synergistic activation of CAGA12
in the presence of both TGFb1 and Bcr-Abl that peaked
around 5 ng/mL TGFb (Fig. 1A). We then examined the eﬀect
of speciﬁc inhibitors on the synergistic CAGA12 activation in
the presence of Bcr-Abl and TGFb. Cos-1 cells transfected
with CAGA12 and Bcr-Abl in the presence or absence of
TGFb were treated with 10 lM of imatinib for 2 h prior to
TGFb stimulation. The synergistic activation of the transcrip-
tional activity of CAGA12 obtained with Bcr-Abl and TGFb
was partially inhibited by imatinib (8-fold increase in presence
of imatinib compared to 25-fold in controls), even though
Bcr-Abl kinase activity was completely inhibited based on
phosphotyrosine Western blotting (Fig. 1B). This suggests
that the inﬂuence of Bcr-Abl on the TGFb signalling cascade
is not exclusively mediated by its’ kinase domain, although we
cannot exclude the possibility that there may be some residual
Bcr-Abl kinase activity that is not detected by anti-phospho-
tyrosine blotting. SB431542 is a potent and selective inhibitor
of the TGFb type I receptor. Cos-1 cells transfected with
CAGA12 and Bcr-Abl, in the presence or absence of TGFb1,
were treated with 10 lM of SB431542 for 2 h prior to TGFb
stimulation. In this instance, synergistic activation of the tran-
scriptional activity of CAGA12 was completely inhibited by
SB431542 which itself had no eﬀect on Bcr-Abl kinase activity
(Fig. 1B). These data suggest that the Bcr-Abl inﬂuenced
upregulation of CAGA12 is mediated by the TGFb type I
receptor activation.
Fig. 1. Upregulation of TGFb signalling by Bcr-Abl in transfected
Cos-1 cells. Cos-1 cells were co-transfected with a Bcr-Abl expression
plasmid or the corresponding empty vector together with a TGFb/
Smad-responsive CAGA12-luciferase reporter construct. (A) Cells
were stimulated for 4 hours with varying concentrations of TGFb1 (0–
10 ng/ml), and the luciferase activity was monitored. Data were
normalised to a control plasmid and are the average of at least three
separate experiments ± S.E. The fold diﬀerences between non-Bcr-Abl
expressing controls vs. TGFb stimulated cells as well as Bcr-Abl
expressing controls vs. TGFb stimulated cells is indicated above the
relevant bars. (B) Cells pre-stimulated for 2 h with either 10 lM of
imatinib, 10 lM of SB431542 or 0.1% DMSO. 5 ng/ml of TGFb1 was
then added to the culture media for 4 h and the luciferase activity was
determined. Data were normalised to a control plasmid and are the
average of at least three separate experiments ± S.E. The fold
diﬀerences between non-Bcr-Abl expressing controls vs. TGFb stim-
ulated cells as well as Bcr-Abl expressing controls vs. TGFb stimulated
cells is indicated above the relevant bars. The bottom panel represents
anti-Abl, anti-b-actin and anti-phosphotyrosine Western blots of cell
lysates used in this experiment.
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Cosl cells
Studies have shown previously that Bcr-Abl can upregulate
gene subsets by targeting speciﬁc promoter elements [13]. In
addition, the activity of important cell signalling regulators
such as protein-tyrosine phosphatase IB (PTP IB) for example
is directly controlled by Bcr-Abl enhancing PTP IB promoteractivity [14]. To begin to investigate the mechanisms driv-
ing increased TGFb signalling activity in the presence of
Bcr-Abl, we initially examined the eﬀect of Bcr-Abl on the pro-
moter activity of receptor-regulated Smad2 and Smad3. Cos-1
cells were transfected with luciferase reporter plasmids con-
taining a 3030 bp human Smad2 promoter fragment referred
to as pGL3-Smad2P [11], or a 1892 bp fragment of the Smad3
promoter known as pGL3-Smad3P [12], together with increas-
ing amounts of a Bcr-Abl expression plasmid. Luciferase
assays showed a signiﬁcant concentration-dependent
upregulation of both the Smad2 and Smad3 promoters in the
presence of Bcr-Abl, with no eﬀect on the empty pGL3b vector
(Fig. 2A and B). Increasing levels of Bcr-Abl expression in
these experiments was also conﬁrmed by anti-abl Western blot-
ting (lower panels in Fig. 2A and B). Changes in Smad pro-
moter activity in the presence of Bcr-Abl were also reﬂected
in increases in endogenous Smad2 and Smad3 protein levels
determined by Western blotting (Fig. 2C). These results sug-
gest that one mechanism for enhanced TGFb signalling activ-
ity in the presence of Bcr-Abl is by increasing the levels of
Smad expression. Although we have also observed no signiﬁ-
cant alterations in rates of Smad translocation and Smad c-ter-
minal phosphorylation in the presence of Bcr-Abl (data not
shown), we cannot rule out additional cross-regulatory mech-
anisms.3.3. TGFb-induced growth arrest is enhanced in myeloid
cells expressing Bcr-Abl and CD34 positive cells from
CP-CML patients
Since expression of Bcr-Abl signiﬁcantly enhanced TGFb/
Smad signalling activity in Cosl cells, we next examined the ef-
fects of TGFb on TF-1 cells, a GM-CSF-dependent myeloid
leukaemic cell line that has been established as a model system
for CML blast crisis [15,16]. A TF-1 cell line stably expressing
Bcr-Abl-GFP was generated as described previously for 32D
cells [9], and Bcr-Abl expression conﬁrmed by anti-Abl Wes-
tern blotting (data not shown). Comparing the growth of
parental TF-1 cells and TF-1/Bcr-Abl cells indicates that
TGFb has a greater growth inhibitory eﬀect on cells expressing
Bcr-Abl (Fig. 3A). After 7 days in culture, there are approxi-
mately 80% of TF-1 cells in TGFb-stimulated relative to
unstimulated controls compared to approximately 55%
remaining in the TF-1/Bcr-Abl cells (Fig. 3A). Therefore, in
a myeloid cell context, the presence of Bcr-Abl does indeed en-
hance cellular responsiveness to TGFb. Next, in order to assess
whether the TGFb growth inhibitory response is active in pri-
mary CML cells, CD34 positive cells from CP-CML patients
were cultured for 7 days with or without TGFb, and also in
the presence of the SB431542 TGFb kinase inhibitor. Growth
and viability were analysed at days 1, 2, 5 and 7. CP-CML pro-
genitor cells were clearly susceptible to the growth inhibitory
eﬀect of TGFb (Fig. 3B). Conversely, inhibition of endogenous
TGFb signalling using SB431542 caused a slight increase in
cell growth compared to the un-stimulated control cells. PI
staining of CP-CML CD34+ cells showed an increase in the
Gl and a decrease in the S-phase sub-populations after 24 h
TGFb stimulation (Fig. 3C). Overall, these results indicate that
TGFb potently inhibits the growth CD34 positive cells from
CP-CML patients expressing Bcr-Abl. However, due to the
diﬃculties associated with obtaining CD34+ cells from non-
CML patients for use as Bcr-Abl negative controls, we are
Fig. 2. Bcr-Abl increases Smad promoter activity and Smad expres-
sion. Cos-1 cells were co-transfected with 2 lg or 5 lg Bcr-Abl
expression plasmid or the corresponding empty vector as indicated,
together with either an empty pGL3 vector (pGL3b), the Smad2 (A) or
Smad3 (B) promoter in a pGL3b luciferase reporter construct. Cells in
these experiments were not treated with TGFb, and the luciferase
activity was determined 24 h after transfection. Data were normalised
to a control plasmid and are the average of at least three exper-
iments ± S.E. Expression of increasing amounts of Bcr-Abl was
conﬁrmed by anti-abl Western blots shown in (A) and (B) as separate
panels below the graphs. (C) Samples from the above experiment
transfected with 5 lg Bcr-Abl expression plasmid or an empty vector
were Western blotted against anti-Smad2, anti-Smad3 or anti-b-actin
antibodies.
Fig. 3. TGFb inhibits the growth of TF-1 myeloid cells more potently
in the presence of Bcr-Abl and CD34+ cells isolated from CML
patients. (A) TF-1 cells or TF-1/Bcr-Abl cells were grown in the
presence absence of 5 ng/ml TGFb for the times indicated. Data are
expressed as percentage of cells remaining after TGFb stimulation
relative to unstimulated controls. Data are the average of triplicates
performed in two separate experiments. (B) CD34 positive cells from
CP-CML patients were grown in the presence of either 5 ng/ml of
TGFb1, 10 lM of SB431542 or a combination of both. Growth was
assessed using an automated cell counter (SYSMEX). Data represent
the average of triplicate experiments on three separate patients
samples ± S.E. (C). Cell cycle analysis was performed following the
staining of cells with PI followed by ﬂow cytometry using a FACScan
ﬂow cytometer (Becton Dickinson), and the data obtained were
analysed using WinMDI and Cylchred. Data are the average of
triplicates performed on two separate patient samples.
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3.4. Inhibition of the TGFb receptor kinase potentiates imatinib-
mediated cell death of CD34 positive cells from CP-CML
patients
CD34 positive cells from CP-CML patients clearly undergo
enhanced and sustained growth when maintained in the pres-ence of added growth factors (Fig. 3B), and these proliferating
cells are known to be acutely sensitive to the Bcr-Abl kinase
inhibitor imatinib which preferentially targets dividing cells
[5]. Interestingly, a small population of residual non-dividing
progenitor cells persist in imatinib-treated CML patients,
and these cells may be the prime cause of disease relapse fol-
lowing imatinib treatment [17,18]. We hypothesised that
upregulation of the growth inhibitory response to TGFb in
CD34+ progenitor cells by Bcr-Abl might contribute to the
maintenance of a non-dividing cell population that is refrac-
tory to imatinib-mediated cell death. Therefore, to begin to
analyse this non-dividing cohort of cells, we studied the eﬀects
of growth factor withdrawal on CD34+ CP-CML cells by
maintenance in media containing no added cytokines with
the addition of fresh media at days 3, 5 and 7 of culture. Even
in the absence of growth factors, more than 50% of the cells
Fig. 4. Inhibition of TGFb signalling in non-cycling CML CD34+
cells potentiates imatinib-mediated cell death. (A) CD34+ CP-CML
cell viability was assessed by counting cells daily using a haemocy-
tometer and identifying non-viable cells using trypan blue exclusion.
Imatinib (1 lM) or Imatinib/SB431542 were added to cytokine free
growth medium from Day 0 as indicated. (B) CD34 positive cells from
CP-CML patients were grown in the presence of either 1 lM of
imatinib alone or in conjunction with 10 lM of SB431542 for eight
days. Cell cycle analysis was performed by staining of cells with PI and
analysis with a FACScan ﬂow cytometer (Becton Dickinson), and the
data obtained were assessed using WinMDI and Cylchred. Data are
the average of triplicate experiments performed on two separate
patient samples.
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it is likely that this subpopulation enters a dormant state, in
which they exit from the cell cycle. After 7 days of exposure
to imatinib approximately 30% of CD34+ CP-CML cells re-
mained viable and the inclusion of the TGFb receptor kinase
inhibitor SB431542 reduced the number further to approxi-
mately 20% (Fig. 4A). Cell cycle analysis of the culture popu-
lation at that time-point showed that imatinib led to an
overwhelming accumulation of live cells in the sub-Gl phase
of the cell cycle (Fig. 4B). However, combined treatment with
both imatinib and SB431542 caused the number of dead cells
in sub-Gl phase to increase dramatically with a concomitant
reduction in the Gl sub-population (Fig. 4B). These results
suggest that dual treatment of CD34+ CP-CML cells main-
tained in the absence of added cytokines with both imatinib
and SB431542 is indeed more eﬀective than imatinib treatment
alone.4. Discussion
The transforming growth factor-b (TGFb) family of growth
factors are important regulators of haemopoietic cell function,
although individual cell lineages can respond positively or neg-
atively depending upon their level of diﬀerentiation and matu-
ration [1,2]. In general, TGFb is considered as a strong
inhibitor of committed progenitor cell growth and diﬀerentia-
tion, and the autocrine production of TGFb maintains imma-
ture CD34+ haemopoietic progenitor cells in a quiescent state.Interestingly, studies of haemopoietic pathologies and leukae-
mias have shown abnormalities in TGFb signalling activity in
both early myeloid leukaemia [19], and lymphocytic leukaemia
[20]. In CML, the oncogenic Bcr-Abl fusion protein drives hae-
mopoietic cell transformation, and also sustains a rare cohort
of quiescent Bcr-Abl+ haemopoietic progenitor cells that per-
sist throughout the CML-CP [21]. In this study, we explored
connections between Bcr-Abl and TGFb signal transduction
pathway in model systems, haemopoietic cell lines and
BcrAbl-expressing CD34+ cells isolated from CP-CML
patients. Initially, we have shown that in TGFb-responsive
Cos-1 cells, the ectopic expression of Bcr-Abl signiﬁcantly
upregulates TGFb mediated transcriptional activity. This phe-
nomenon is mediated by the TGFb type I receptor and partly
by the kinase domain of Bcr-Abl. We then demonstrated that
TGFb has a signiﬁcantly greater growth inhibitory eﬀect on
myeloid TF-1 cells expressing Bcr-Abl compared to the paren-
tal TF-1 cell line. In addition, TGFb potently inhibits the
growth of BcrAbl-expressing CD34+ cells isolated from CP-
CML patients by inducing cell cycle arrest. Finally, we show
that inhibition of the TGFb receptor kinase in a quiescent
sub-population of these Bcr-Abl-expressing CD34+ cells over-
comes the cell cycle blockade by TGFb, and enhances their
sensitivity to cell death mediated by the Bcr-Abl kinase inhib-
itor imatinib.
We have shown for the ﬁrst time that the expression of Bcr-
Abl can act synergistically to upregulate TGFb transcriptional
activity in Cos-1 cells transfected with the TGFb-responsive
CAGA12 luciferase reporter. Initially, this was an unexpected
result since several reports have demonstrated that TGFb
signalling and Smad functional activity is generally inhibited
by intracellular signalling cascades downstream of receptor
tyrosine kinases [22–25]. In these instances, the cross-talk
mechanisms generally involve eﬀects on Smad nuclear translo-
cation. In our experiments, Bcr-Abl does not prevent TGFb-
induced movement of Smads into the nucleus. However, here
we show that Bcr-Abl does increase the activity of both a
3030 bp fragment of the human Smad2 promoter, and an
1892 bp fragment of the Smad3 promoter, and also increases
Smad2 and Smad3 protein expression. Therefore, the synergis-
tic activation of TGFb signalling activity in the presence of
Bcr-Abl could be due to a direct eﬀect of signalling pathways
downstream of Bcr-Abl on Smad promoter activity, leading
to increased Smad expression and enhanced activation of the
TGFb signalling pathway.
The ﬁnal results presented investigate the more physiological
aspect of TGFb signalling in the context of CML. Strong inhi-
bition of BcrAbl-expressing CD34+ cells isolated from CP-
CML patients suggests that Bcr-Abl is not able to inhibit
TGFb signalling in a pathophysiological context. This re-
sponse is likely to be cell type dependent, and this may explain
why our data contrast with a recent report suggesting that in
Ba/F3 and K562 cells, Bcr-Abl inhibits the cytostatic eﬀect
of TGFb through the AKT/FoxO3 signalling pathway [26].
We have also observed that K562 cells are insensitive to
TGFb-mediated growth inhibition (data not shown). How-
ever, in our study, it is clear that CD34+ cells isolated from
CML patients are highly responsive to the cytostatic action
of TGFb, even thought they express Bcr-Abl. In addition,
we ﬁnd that the expression of Bcr-Abl in a myeloid TF-1 cell
background enhances their responsiveness to the TGFb
growth inhibitory activity.
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TGFb is a strong inhibitor of haemopoietic cell growth and
diﬀerentiation. The complete eradication of CML is also hin-
dered by a small pocket of haemopoietic stem cells which are
resistant to imatinib, in part because they are non-cycling [6].
Therefore, TGFb is a prime candidate for maintaining these
haemopoietic stem cells in a non-cycling state. Furthermore,
we have demonstrated an upregulation or prolongation of
TGFb signalling by Bcr-Abl, which would suggest that one
of the mechanisms by which Bcr-Abl promotes the transforma-
tion of haemopoietic progenitor cells, is by inﬂuencing the level
of TGFb signalling activity. We therefore believe that TGFb
could play a vital role in the preservation of the malignant pro-
genitor population, and be partly responsible for the resistance
to treatments targeting Bcr-Abl that is observed in a propor-
tion of CML patients. Our ﬁndings are also interesting in light
of recent mathematical models of CML which propose that
combination treatment of imatinib with a cell cycle stimulant
of progenitor cells could be eﬀective in eliminating disease per-
sistence in CML [27]. An important goal for the future is to
study the eﬀects of TGFb on CML patient cells at diﬀerent
stages of diﬀerentiation to elucidate cross-regulatory mecha-
nisms during chronic phase, accelerated phase and blast crisis.
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